tetano
Editor, Senior Moderator
J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14858. [Epub ahead of print]
Potential of Heparin and Nafamostat Combination Therapy for COVID-19.
Asakura H[SUP]1[/SUP], Ogawa H[SUP]2[/SUP].
Author information
Abstract
Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases.
This article is protected by copyright. All rights reserved.
PMID:32302456DOI:10.1111/jth.14858
Potential of Heparin and Nafamostat Combination Therapy for COVID-19.
Asakura H[SUP]1[/SUP], Ogawa H[SUP]2[/SUP].
Author information
Abstract
Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases.
This article is protected by copyright. All rights reserved.
PMID:32302456DOI:10.1111/jth.14858